Teclistamab-cqyv for Relapsed/Refractory Multiple Myeloma

home / approval-alert / teclistamab-cqyv-for-relapsed-refractory-multiple-myeloma

Teclistamab-cqyv for Relapsed/Refractory Multiple Myeloma

In October 22, the FDA granted accelerated approval to teclistamab-cqvy for patients with relapsed/refractory multiple myeloma.

Articles

$FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma$

FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma

October 25th 2022

Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval to teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.

Videos

Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.

Joseph Mikhael, MD, Discusses the FDA’s Approval of Teclistimab-cqyv in Relapsed/Refractory Multiple Myeloma

October 26th 2022

Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777